当前位置: 首页 >> 检索结果
182. Targeting Stem Cells in Chronic Myeloid Leukemia with a PPAR-γ Agonist.
Combining a tyrosine kinase inhibitor (imatinib) and a thiazolidinedione (pioglitazone) is proposed for the treatment of chronic myeloid leukemia.
183. Case Records of the Massachusetts General Hospital. Case 35-2015: A 72-Year-Old Woman with Proteinuria and a Kidney Mass.
作者: D Bora Hazar.;Nwamaka D Eneanya.;Aoife Kilcoyne.;Ivy A Rosales.
来源: N Engl J Med. 2015年373卷20期1958-67页
A 72-year-old woman presented with flank pain, proteinuria, and a new kidney mass. Magnetic resonance imaging of the kidney revealed a complex, solid mass (3 cm x 2.9 cm x 2.9 cm) in the lower pole of the right kidney. Diagnostic tests were performed.
184. Images in Clinical Medicine. Left Main Coronary Artery Stent Migration.
A 22-year-old woman with primary pulmonary hypertension presented with displacement of stents that had been implanted in the left main coronary artery and had migrated into the aorta. She had been referred to our center for evaluation for lung transplantation.
185. Elder Abuse.
Because older victims of abuse tend to be isolated, their interactions with physicians are important opportunities to recognize abuse and intervene. This review explores the manifestations of elder abuse and the role of multidisciplinary teams in its assessment and management.
186. Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease.
作者: Steven P Sedlis.;Pamela M Hartigan.;Koon K Teo.;David J Maron.;John A Spertus.;G B John Mancini.;William Kostuk.;Bernard R Chaitman.;Daniel Berman.;Jeffrey D Lorin.;Marcin Dada.;William S Weintraub.;William E Boden.; .
来源: N Engl J Med. 2015年373卷20期1937-46页
Percutaneous coronary intervention (PCI) relieves angina in patients with stable ischemic heart disease, but clinical trials have not shown that it improves survival. Between June 1999 and January 2004, we randomly assigned 2287 patients with stable ischemic heart disease to an initial management strategy of optimal medical therapy alone (medical-therapy group) or optimal medical therapy plus PCI (PCI group) and did not find a significant difference in the rate of survival during a median follow-up of 4.6 years. We now report the rate of survival among the patients who were followed for up to 15 years.
187. The Genetic Evolution of Melanoma from Precursor Lesions.
作者: A Hunter Shain.;Iwei Yeh.;Ivanka Kovalyshyn.;Aravindhan Sriharan.;Eric Talevich.;Alexander Gagnon.;Reinhard Dummer.;Jeffrey North.;Laura Pincus.;Beth Ruben.;William Rickaby.;Corrado D'Arrigo.;Alistair Robson.;Boris C Bastian.
来源: N Engl J Med. 2015年373卷20期1926-36页
The pathogenic mutations in melanoma have been largely catalogued; however, the order of their occurrence is not known.
188. Maryland's Global Hospital Budgets--Preliminary Results from an All-Payer Model.
作者: Ankit Patel.;Rahul Rajkumar.;John M Colmers.;Donna Kinzer.;Patrick H Conway.;Joshua M Sharfstein.
来源: N Engl J Med. 2015年373卷20期1899-901页
In the first year of Maryland's experiment in setting all-payer rates for hospital services, costs were contained and the quality of care improved, though the state still has high rates of hospital admissions and per capita spending for Medicare patients.
189. The Path to Cancer --Three Strikes and You're Out.
Focusing on driver-gene mutations and the pathways they control has rendered complex cancer-genome landscapes intelligible. In solid tumors of adults, alterations in as few as three driver genes appear to suffice for a cell to evolve into an advanced cancer.
190. Reviewing Peer Review at the NIH.
Recent reports suggest that peer reviews of National Institutes of Health grant applications are at best imprecise predictors of research projects' scientific impact. But these findings may not mean that peer review is failing.
192. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
作者: Deborah M Siegal.;John T Curnutte.;Stuart J Connolly.;Genmin Lu.;Pamela B Conley.;Brian L Wiens.;Vandana S Mathur.;Janice Castillo.;Michele D Bronson.;Janet M Leeds.;Florie A Mar.;Alex Gold.;Mark A Crowther.
来源: N Engl J Med. 2015年373卷25期2413-24页
Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. Andexanet is designed to reverse the anticoagulant effects of factor Xa inhibitors.
195. A Leadless Intracardiac Transcatheter Pacing System.
作者: Dwight Reynolds.;Gabor Z Duray.;Razali Omar.;Kyoko Soejima.;Petr Neuzil.;Shu Zhang.;Calambur Narasimhan.;Clemens Steinwender.;Josep Brugada.;Michael Lloyd.;Paul R Roberts.;Venkata Sagi.;John Hummel.;Maria Grazia Bongiorni.;Reinoud E Knops.;Christopher R Ellis.;Charles C Gornick.;Matthew A Bernabei.;Verla Laager.;Kurt Stromberg.;Eric R Williams.;J Harrison Hudnall.;Philippe Ritter.; .
来源: N Engl J Med. 2016年374卷6期533-41页
A leadless intracardiac transcatheter pacing system has been designed to avoid the need for a pacemaker pocket and transvenous lead.
199. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
作者: .;Jackson T Wright.;Jeff D Williamson.;Paul K Whelton.;Joni K Snyder.;Kaycee M Sink.;Michael V Rocco.;David M Reboussin.;Mahboob Rahman.;Suzanne Oparil.;Cora E Lewis.;Paul L Kimmel.;Karen C Johnson.;David C Goff.;Lawrence J Fine.;Jeffrey A Cutler.;William C Cushman.;Alfred K Cheung.;Walter T Ambrosius.
来源: N Engl J Med. 2015年373卷22期2103-16页
The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain.
|